Ambagon Therapeutics Inc. — Form D/A
Ambagon Therapeutics Inc. of Eindhoven, P7, a company, filed a Form D amendment with the SEC on 2022-06-01. The offering totals $85.0M, of which $45.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2022-06-01
- Form: D/A
- Accession: 0001819934-22-000003
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $85.0M
- Amount sold: $45.0M
- Remaining: $40.0M
- Investors: 9
- Date of first sale: 2022-01-05
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-429995
Issuer
- Name: Ambagon Therapeutics Inc.
- CIK: 0001819934
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2020
- Address: De Lismortel 31, Catalyst Business Ctr, Eindhoven, P7, 5612 AR
- Phone: 31 40 7517694
Officers, directors & promoters (15)
| Name | Role | Location |
|---|
| Michelle Arkin | Director | San Francisco, CA |
| Roel Bulthuis | Director | San Francisco, CA |
| Margarita Chavez | Director | San Francisco, CA |
| Scott Clarke | Director | San Francisco, CA |
| Peter Dudek | Director | San Francisco, CA |
| Janwillem Naesens | Director | San Francisco, CA |
| Adam Rosenberg | Director | Wilmington, DE |
| Scott Clarke | Executive Officer | San Francisco, CA |
| Bryan Miller | Executive Officer | Guaynabo, PR |
| Nancy Pryer | Executive Officer | San Francisco, CA |
| Melissa McCracken | Director | Eindhoven, P7 |
| Josh Seidenfeld | Executive Officer | Palo Alto, CA |
| Christian Ottmann | Executive Officer | Eindhoven, P7 |
| Michelle Arkin | Executive Officer | San Francisco, CA |
| Lucas Brunsveld | Executive Officer | San Francisco, CA |
Other filings by this issuer (5)
More